Article Details
Retrieved on: 2018-02-01 04:48:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>... AVROBIO has carved out a strong position with its lentiviral platform focused on the significant therapeutic and market opportunities for gene therapies for lysosomal storage diseases,” said Bruce Booth, D.Phil., Partner at <b>Atlas Venture</b> and Chairman of AVROBIO's Board of Directors in a press release.</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here